申请人:Yamaguchi University
公开号:EP2918290A1
公开(公告)日:2015-09-16
The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a RARγ agonist as an active ingredient is provided. The therapeutic agent exhibits an excellent ameliorating effect in a keratoconjunctive disorder model, and is therefore useful as a therapeutic agent for keratoconjunctive disorders such as corneal ulcer, corneal epithelial abrasion, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal erosion, persistent corneal disorders, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, infectious keratitis, noninfectious keratitis, infectious conjunctivitis and noninfectious conjunctivitis. The therapeutic agent is also useful as a therapeutic agent for corneal scarring and conjunctival scarring both associated with keratoconjunctive disorders.
本发明要解决的问题是提供一种新型的角结膜病治疗剂。作为解决问题的一种方法,本发明提供了一种角膜结膜病治疗剂,其活性成分中含有一种 RARγ 激动剂。该治疗剂在角膜结膜疾病模型中表现出极佳的改善效果,因此可用作角膜结膜疾病的治疗剂,如角膜溃疡、角膜上皮擦伤、角膜炎、干眼症、结膜炎、慢性浅表角膜炎、角膜糜烂、持续性角膜病变、浅表点状角膜病、角膜上皮缺损、结膜上皮缺损、固执性角膜结膜炎、上肢角膜结膜炎、丝状角膜结膜炎、感染性角膜炎、非感染性角膜炎、感染性结膜炎和非感染性结膜炎。这种治疗剂还可用于治疗与角结膜炎相关的角膜瘢痕和结膜瘢痕。